Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2003

01.12.2003 | Short Communication

Heparan sulphate epitope–expression is associated with the inflammatory response in metastatic malignant melanoma

verfasst von: Monique R. Bernsen, Toon F. C. M. Smetsers, Els van de Westerlo, Dirk J. Ruiter, Leif Håkansson, Bertil Gustafsson, Toin H. van Kuppevelt, Lennart Krysander, Björn Rettrup, Annika Håkansson

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2003

Einloggen, um Zugang zu erhalten

Abstract

Heparan sulphate (HS) represents a heterogeneous class of molecules on cell membranes and extracellular matrices. These molecules are involved in a variety of biological processes, including immune responses, through their binding and functional modulation of proteins. Recently a panel of HS-epitope–specific, human single chain antibodies have been generated by phage display, facilitating analysis of the structural heterogeneity of HS in relation to pathological conditions. In a pilot study a heterogeneous staining pattern in melanoma metastases was observed with one of the clones (EW4G1). Using a double-staining technique, the expression of this epitope was studied in 12 metastatic melanoma lesions in relation to the presence of a CD3+ cell infiltrate. Different staining patterns with EW4G1 were observed in the different lesions. The different staining patterns were associated with the presence and pattern of inflammation with CD3+ cells. A pronounced staining pattern of blood vessels with EW4G1 was associated with a more or less brisk presence of CD3+ cells, while a pronounced staining of tumour cells or tumour cell matrix or absence of staining with EW4G1 was associated with absence of CD3+ cells. These results suggest a dualistic role for HS in the recruitment and intratumoural migration of CD3+ cells, depending on the location of expression of its epitope recognized by EW4G1. Further characterization of the structural diversity of HS and its function in T-cell recruitment and migration is therefore warranted, since detailed understanding of this relation may provide new targets for therapeutic intervention, such that better homing and migration of T cells (in)to tumours might be achieved in immunologically based treatment strategies.
Literatur
1.
Zurück zum Zitat Caux F, Timar J, Lapis K, Moczar M (1990) Proteochondroitin sulphate in human melanoma cell cultures. Biochem Soc Trans 18:293PubMed Caux F, Timar J, Lapis K, Moczar M (1990) Proteochondroitin sulphate in human melanoma cell cultures. Biochem Soc Trans 18:293PubMed
2.
Zurück zum Zitat Ey PL, Prowse SJ, Jenkin CR (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15:429CrossRefPubMed Ey PL, Prowse SJ, Jenkin CR (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15:429CrossRefPubMed
3.
Zurück zum Zitat Hershkoviz R, Schor H, Ariel A, Hecht I, Cohen IR, Lider O, Cahalon L (2000) Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix. Immunology 99:87CrossRef Hershkoviz R, Schor H, Ariel A, Hecht I, Cohen IR, Lider O, Cahalon L (2000) Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix. Immunology 99:87CrossRef
4.
Zurück zum Zitat Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881PubMed Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881PubMed
5.
Zurück zum Zitat Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273:24979CrossRef Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273:24979CrossRef
6.
Zurück zum Zitat Lortat-Jacob H, Grimaud JA (1991) Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell Mol Biol 37:253PubMed Lortat-Jacob H, Grimaud JA (1991) Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell Mol Biol 37:253PubMed
7.
Zurück zum Zitat Moczar M, Caux F, Bailly M, Berthier O, Dore JF (1993) Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability. Clin Exp Metastasis 11:462PubMed Moczar M, Caux F, Bailly M, Berthier O, Dore JF (1993) Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability. Clin Exp Metastasis 11:462PubMed
8.
Zurück zum Zitat Nathan C, Sporn M (1991) Cytokines in context. J Cell Biol 113:981PubMed Nathan C, Sporn M (1991) Cytokines in context. J Cell Biol 113:981PubMed
9.
Zurück zum Zitat Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: a piece of information. FASEB J 10:1270PubMed Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: a piece of information. FASEB J 10:1270PubMed
10.
Zurück zum Zitat Selvan RS, Ihrcke NS, Platt JL (1996) Heparan sulfate in immune responses. Ann N Y Acad Sci 797:127PubMed Selvan RS, Ihrcke NS, Platt JL (1996) Heparan sulfate in immune responses. Ann N Y Acad Sci 797:127PubMed
11.
Zurück zum Zitat Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT (1992) Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267:10337PubMed Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT (1992) Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267:10337PubMed
12.
Zurück zum Zitat van de Westerlo EM, Smetsers TF, Dennissen MA, Linhardt RJ, Veerkamp JH, van Muijen GN, van Kuppevelt TH (2002) Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 99:2427CrossRefPubMed van de Westerlo EM, Smetsers TF, Dennissen MA, Linhardt RJ, Veerkamp JH, van Muijen GN, van Kuppevelt TH (2002) Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 99:2427CrossRefPubMed
13.
Zurück zum Zitat van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH (1998) Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273:12960CrossRefPubMed van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH (1998) Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273:12960CrossRefPubMed
14.
Zurück zum Zitat Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9:203PubMed Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9:203PubMed
Metadaten
Titel
Heparan sulphate epitope–expression is associated with the inflammatory response in metastatic malignant melanoma
verfasst von
Monique R. Bernsen
Toon F. C. M. Smetsers
Els van de Westerlo
Dirk J. Ruiter
Leif Håkansson
Bertil Gustafsson
Toin H. van Kuppevelt
Lennart Krysander
Björn Rettrup
Annika Håkansson
Publikationsdatum
01.12.2003
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2003
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-003-0421-8

Weitere Artikel der Ausgabe 12/2003

Cancer Immunology, Immunotherapy 12/2003 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.